22091-39-0

Basic information

• Product Name: 4-CHLOROMETHYL-2-(4-FLUOROPHENYL) OXAZOLE
• Synonyms: 4-CHLOROMETHYL-2-(4-FLUOROPHENYL) OXAZOLE;4-FCPO
• CAS NO: 22091-39-0
• Molecular Formula: C₁₀H₇ClFNO
• Molecular Weight: 211.62
• Mol File: 22091-39-0.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 316.64°C at 760 mmHg
• Flash Point: 145.299°C
• Appearance: /
• Density: 1.301g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.54
• CAS DataBase Reference: 4-CHLOROMETHYL-2-(4-FLUOROPHENYL) OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROMETHYL-2-(4-FLUOROPHENYL) OXAZOLE(22091-39-0)
• EPA Substance Registry System: 4-CHLOROMETHYL-2-(4-FLUOROPHENYL) OXAZOLE(22091-39-0)

Safety Data

• Hazardous Substances Data: 22091-39-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H7ClFNO/c11-5-9-6-14-10(13-9)7-1-3-8(12)4-2-7/h1-4,6H,5H2

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 1065102-64-8 methyl 2-(4-fluorophenyl)-1,3-oxazole-4-carboxylate 
• 456-22-4 4-Fluorobenzoic acid 
• 403-43-0 4-fluorobenzoyl chloride 
• 885273-80-3 (2-(4-fluorophenyl)oxazol-4-yl)methanol 
• 824-75-9 p-fluorobenzamide 
• 534-07-6 1,3-Dichloroacetone 

Downstream Products

• 1589081-04-8 4-amino-6-(benzo[d][1,3]dioxol-5-yl)-2-((2-(4-fluorophenyl)oxazol-4-yl)methylthio)pyrimidine-5-carbonitrile 
• 1314887-18-7 4-(2-(4-fluorophenyl)oxazol-4-yl)-1-methylpiperidine-4-carbonitrile 
• 885272-89-9 (2-(4-fluorophenyl)oxazol-4-yl)methanamine 
• 1016734-82-9 2-(2-(4-fluorophenyl)oxazol-4-yl)ethanamine 
• 1314887-16-5 3-(2-(4-fluorophenyl)oxazol-4-yl)-N₁,N₁-dimethylbutane-1,4-diamine 
• 1314887-15-4 4-(dimethylamino)-2-(2-(4-fluorophenyl)oxazol-4-yl)butanenitrile 
• 22087-28-1 2-(2-(4-fluorophenyl)oxazol-4-yl)acetonitrile 
• 877880-12-1 C₂₁H₂₆FNO₄ 

Relevant articles and documents

Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents

The benzothiazinone (BTZ) scaffold compound PBTZ169 kills Mycobacterium tuberculosis by inhibiting the essential flavoenzyme DprE1, consequently blocking the synthesis of the cell wall component arabinans. While extraordinarily potent against M. tuberculosis with a minimum inhibitory concentration (MIC) less than 0.2 ng/mL, its low aqueous solubility and bioavailability issues need to be addressed. Here, we designed and synthesized a series of 6-methanesulfonyl substituted BTZ analogues; further exploration introduced five-member aromatic heterocycles as linkers to attach an aryl group as the side chain. Our work led to the discovery of a number of BTZ derived compounds with potent antitubercular activity. The optimized compounds 6 and 38 exhibited MIC 47 and 30 nM, respectively. Compared to PBTZ169, both compounds displayed increased aqueous solubility and higher stability in human liver microsomes. This study suggested that an alternative side-chain modification strategy could be implemented to improve the druglike properties of the BTZ-based compounds.

Synthesis and bioactivity of novel pyrazole oxime derivatives containing oxazole ring

Abstract A series of novel pyrazole oxime derivatives containing oxazole ring were designed and synthesized. The title compounds were structurally confirmed by 1H NMR, 13C NMR spectra and elemental analyses. Preliminary bioassay results showed that some of the title compounds displayed promising fungicidal activity besides insecticidal and acaricidal activity. Particularly, compound 8c exhibited potent fungicidal activity against cucumber Pseudoperonospora cubensis beyond good insecticidal activity against Aphis craccivora and Nilaparvata lugens.

Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi- and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb.